Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma

Dirk Rades*, Stefan Huttenlocher, Niklas Gebauer, Dagmar Hornung, Ngo Thuy Trang, Mai Trong Khoa, Steven E. Schild

*Corresponding author for this work
5 Citations (Scopus)

Abstract

Aim: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types. Patients and Methods: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy. Results: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006). Conclusion: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.

Original languageEnglish
JournalAnticancer Research
Volume35
Issue number6
Pages (from-to)3571-3574
Number of pages4
ISSN0250-7005
Publication statusPublished - 01.01.2015

Fingerprint

Dive into the research topics of 'Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma'. Together they form a unique fingerprint.

Cite this